TY - JOUR
T1 - Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section
AU - Dansereau, J.
AU - Joshi, A. K.
AU - Helewa, M. E.
AU - Doran, T. A.
AU - Lange, I. R.
AU - Luther, E. R.
AU - Farine, D.
AU - Schulz, M. L.
AU - Horbay, G. L.A.
AU - Griffin, P.
AU - Wassenaar, W.
N1 - Funding Information:
Supported by a clinical research grant from Ferring Inc., Canada.
PY - 1999
Y1 - 1999
N2 - OBJECTIVE: The goal of this study was to compare carbetocin, a long- acting oxytocin analog, with oxytocin in the prevention of uterine atony after cesarean section. STUDY DESIGN: We enrolled 694 patients undergoing elective cesarean section in a Canadian multicenter, double-blind, randomized clinical trial. We compared the effect of a single 100 μg dose of carbetocin with that of a standard 8-hour infusion of oxytocin. The primary outcome was the proportion of patients requiring additional oxytocic intervention for uterine atony. A variable sample size, sequential design was used. RESULTS: The overall oxytocic intervention rate was 7.4%. The odds of treatment failure requiring oxytocic intervention was 2.03 (95% confidence interval 1.1 to 2.8) times higher in the oxytocin group compared with the carbetocin group, respectively, 32 of 318 (10.1%) versus 15 of 317 (4.7%), P < .05. CONCLUSIONS: Carbetocin, a new drug for the prevention of uterine atony, appears to be more effective than a continuous infusion of oxytocin and has a similar safety profile.
AB - OBJECTIVE: The goal of this study was to compare carbetocin, a long- acting oxytocin analog, with oxytocin in the prevention of uterine atony after cesarean section. STUDY DESIGN: We enrolled 694 patients undergoing elective cesarean section in a Canadian multicenter, double-blind, randomized clinical trial. We compared the effect of a single 100 μg dose of carbetocin with that of a standard 8-hour infusion of oxytocin. The primary outcome was the proportion of patients requiring additional oxytocic intervention for uterine atony. A variable sample size, sequential design was used. RESULTS: The overall oxytocic intervention rate was 7.4%. The odds of treatment failure requiring oxytocic intervention was 2.03 (95% confidence interval 1.1 to 2.8) times higher in the oxytocin group compared with the carbetocin group, respectively, 32 of 318 (10.1%) versus 15 of 317 (4.7%), P < .05. CONCLUSIONS: Carbetocin, a new drug for the prevention of uterine atony, appears to be more effective than a continuous infusion of oxytocin and has a similar safety profile.
UR - http://www.scopus.com/inward/record.url?scp=0033019957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033019957&partnerID=8YFLogxK
U2 - 10.1016/S0002-9378(99)70271-1
DO - 10.1016/S0002-9378(99)70271-1
M3 - Article
C2 - 10076146
AN - SCOPUS:0033019957
SN - 0002-9378
VL - 180
SP - 670
EP - 676
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 3 I
ER -